1. Emerging Considerations in the Use of Immune Checkpoint Inhibitors: CRC

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. MSI Status and Immunologic Response

5. Pembrolizumab

6. Pembrolizumab Updates

7. Nivolumab

8. Nivolumab Updates

9. Atezolizumab

10. MSS Tumors and Immunotherapy

11. Strategies to Convert Noninflamed Tumors to Inflamed Tumors

12. Strategies to Convert Noninflamed Tumors to Inflamed Tumors (cont)

13. Real World Practice

14. Candidates for Checkpoint Inhibition

15. Pseudoprogression

16. Immune-Related AEs

17. Concluding Remarks